JCR Pharma, Ordinary Profit Forecast for Last Fiscal Year Revised Upward by 2.8 times

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Mon May 11, 2026 3:30 pm JST Revision

4552 JCR Pharmaceuticals Co.,Ltd. 【J-GAAP】

Guidance Update Report

JCR Pharmaceuticals Co.,Ltd. <4552> [TSE Prime] announced a performance revision after the market closed on May 11th (15:30). The consolidated ordinary profit forecast for the fiscal year ending March 2026 has been revised upward 2.8 times, from the previous forecast of 0.40 billion yen to 1.10 billion yen (compared to a loss of 7.47 billion yen in the previous period).

Based on the upwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (second half) consolidated ordinary profit/loss has been revised upward from an expected loss of 1.96 billion yen to a loss of 1.26 billion yen (compared to a loss of 5.85 billion yen in the same period of the previous year), indicating a reduction in the loss margin.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2025 Prev	18,138	-1,979	-1,962	-110	-0.9	10	Jan 28, 2026	J-GAAP
Oct - Mar, 2025 New	18,938	-1,879	-1,262	390	3.3	10	May 11, 2026	J-GAAP
Revision Rate	+4.4%	+5.1%	+35.7%	－	－

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2026 Prev	39,500	400	400	1,600	13.1	20	Jan 28, 2026	J-GAAP
Mar, 2026 New	40,300	500	1,100	2,100	17.9	20	May 11, 2026	J-GAAP
Revision Rate	+2.0%	+25.0%	+175.0%	+31.3%	+36.2%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024	16,415	-5,480	-5,425	-3,769	-30.4	10	May 13, 2025	J-GAAP
Oct - Mar, 2025 Guidance	18,938	-1,879	-1,262	390	3.3	10	May 11, 2026	J-GAAP
YoY	+15.4%	+65.7%	+76.7%	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2024	42,871	7,531	7,264	5,507	44.1	20	May 10, 2024	J-GAAP
Mar, 2025	33,072	-6,219	-7,046	-4,460	-36.0	20	May 13, 2025	J-GAAP
Mar, 2026 Guidance	40,300	500	1,100	2,100	17.9	20	May 11, 2026	J-GAAP
YoY	+21.9%	－	－	－	－